New combo aims to tame advanced cervical cancer with fewer side effects
NCT ID NCT07143292
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests three different doses of the drug famitinib combined with camrelizumab in 120 people with recurrent or metastatic cervical cancer that cannot be cured by standard treatments. The goal is to find a dose that keeps the cancer under control while causing fewer severe side effects. Participants will take famitinib daily and receive camrelizumab infusions, and researchers will monitor how long the cancer stays stable and how well the treatment is tolerated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple HPV swab or blood test may spot returning cervical cancer earlier
- New hope for advanced cervical cancer: drug combo trial launches
- New drug combo shows promise for tough cervical cancers
- New drug SLV-154 enters human testing for Hard-to-Treat cancers
- New combo therapy shows promise for Hard-to-Treat cervical cancer